Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed

Elena Di Gennaro, Francesca Bruzzese, Stefano Pepe, Alessandra Leone, Paolo Delrio, Subbayan Pochi, Antonio Avallone, Alfredo Budillon

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Despite the introduction of several novel anticancer agents almost 50% of colorectal cancer (CRC) patients die for cancer suggesting the necessity of new therapeutical approaches. In this study we demonstrated that the HDAC inhibitor vorinostat exerted potent antiproliferative effect in a panel of mut- and wt-p53 human CRC cell lines. Moreover, in combination with 5-fluorouracil modulated by folinic acid (5FU-FA) or with Raltitrexed (RTX), both commonly used in the treatment of this disease, it showed a clear schedule-dependent synergistic antiproliferative interaction as demonstrated by calculating combination indexes. Only simultaneous, or 24 h pretreatment with vorinostat followed by either agent, produced synergistic effect paralleled by evident cell cycle perturbations with major S-phase arrest. Moreover, we provided for the first time evidences that vorinostat can overcome resistance to both 5FU and RTX. Downmodulation of Thymidilate synthase (TS) protein induced by vorinostat within 24 h, represented a key factor in enhancing the effects of both drugs in sensitive as well as resistant tumor cells. Furthermore, p53, whose wildtype expression is critical for sensitivity to 5FU and RTX, was upregulated by vorinostat in wt- and downregulated in mut-p53 cells, suggesting an additional mechanism of the antiproliferative synergistic interactions observed. Overall these data add new insights in the mechanism of vorinostat antitumor effect and suggested that the association of vorinostat plus 5FU-FA and/or RTX should be clinically explored.

Original languageEnglish
Pages (from-to)782-791
Number of pages10
JournalCancer Biology and Therapy
Volume8
Issue number9
StatePublished - May 1 2009

Fingerprint

Histone Deacetylase Inhibitors
Fluorouracil
Leucovorin
Colorectal Neoplasms
raltitrexed
vorinostat
S Phase
Antineoplastic Agents
Neoplasms
Appointments and Schedules
Cell Cycle
Down-Regulation
Cell Line
Pharmaceutical Preparations

Keywords

  • 5-fluorouracil
  • Colorectal cancer
  • HDAC inhibitor
  • p53
  • Raltitrexed
  • Thimidilate synthase
  • Vorinostat

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology

Cite this

Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed. / Di Gennaro, Elena; Bruzzese, Francesca; Pepe, Stefano; Leone, Alessandra; Delrio, Paolo; Pochi, Subbayan; Avallone, Antonio; Budillon, Alfredo.

In: Cancer Biology and Therapy, Vol. 8, No. 9, 01.05.2009, p. 782-791.

Research output: Contribution to journalArticle

Di Gennaro, E, Bruzzese, F, Pepe, S, Leone, A, Delrio, P, Pochi, S, Avallone, A & Budillon, A 2009, 'Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed', Cancer Biology and Therapy, vol. 8, no. 9, pp. 782-791.
Di Gennaro, Elena ; Bruzzese, Francesca ; Pepe, Stefano ; Leone, Alessandra ; Delrio, Paolo ; Pochi, Subbayan ; Avallone, Antonio ; Budillon, Alfredo. / Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed. In: Cancer Biology and Therapy. 2009 ; Vol. 8, No. 9. pp. 782-791.
@article{ae5809e63b5749f2a22dacba9ba9dd43,
title = "Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed",
abstract = "Despite the introduction of several novel anticancer agents almost 50{\%} of colorectal cancer (CRC) patients die for cancer suggesting the necessity of new therapeutical approaches. In this study we demonstrated that the HDAC inhibitor vorinostat exerted potent antiproliferative effect in a panel of mut- and wt-p53 human CRC cell lines. Moreover, in combination with 5-fluorouracil modulated by folinic acid (5FU-FA) or with Raltitrexed (RTX), both commonly used in the treatment of this disease, it showed a clear schedule-dependent synergistic antiproliferative interaction as demonstrated by calculating combination indexes. Only simultaneous, or 24 h pretreatment with vorinostat followed by either agent, produced synergistic effect paralleled by evident cell cycle perturbations with major S-phase arrest. Moreover, we provided for the first time evidences that vorinostat can overcome resistance to both 5FU and RTX. Downmodulation of Thymidilate synthase (TS) protein induced by vorinostat within 24 h, represented a key factor in enhancing the effects of both drugs in sensitive as well as resistant tumor cells. Furthermore, p53, whose wildtype expression is critical for sensitivity to 5FU and RTX, was upregulated by vorinostat in wt- and downregulated in mut-p53 cells, suggesting an additional mechanism of the antiproliferative synergistic interactions observed. Overall these data add new insights in the mechanism of vorinostat antitumor effect and suggested that the association of vorinostat plus 5FU-FA and/or RTX should be clinically explored.",
keywords = "5-fluorouracil, Colorectal cancer, HDAC inhibitor, p53, Raltitrexed, Thimidilate synthase, Vorinostat",
author = "{Di Gennaro}, Elena and Francesca Bruzzese and Stefano Pepe and Alessandra Leone and Paolo Delrio and Subbayan Pochi and Antonio Avallone and Alfredo Budillon",
year = "2009",
month = "5",
day = "1",
language = "English",
volume = "8",
pages = "782--791",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "9",

}

TY - JOUR

T1 - Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed

AU - Di Gennaro, Elena

AU - Bruzzese, Francesca

AU - Pepe, Stefano

AU - Leone, Alessandra

AU - Delrio, Paolo

AU - Pochi, Subbayan

AU - Avallone, Antonio

AU - Budillon, Alfredo

PY - 2009/5/1

Y1 - 2009/5/1

N2 - Despite the introduction of several novel anticancer agents almost 50% of colorectal cancer (CRC) patients die for cancer suggesting the necessity of new therapeutical approaches. In this study we demonstrated that the HDAC inhibitor vorinostat exerted potent antiproliferative effect in a panel of mut- and wt-p53 human CRC cell lines. Moreover, in combination with 5-fluorouracil modulated by folinic acid (5FU-FA) or with Raltitrexed (RTX), both commonly used in the treatment of this disease, it showed a clear schedule-dependent synergistic antiproliferative interaction as demonstrated by calculating combination indexes. Only simultaneous, or 24 h pretreatment with vorinostat followed by either agent, produced synergistic effect paralleled by evident cell cycle perturbations with major S-phase arrest. Moreover, we provided for the first time evidences that vorinostat can overcome resistance to both 5FU and RTX. Downmodulation of Thymidilate synthase (TS) protein induced by vorinostat within 24 h, represented a key factor in enhancing the effects of both drugs in sensitive as well as resistant tumor cells. Furthermore, p53, whose wildtype expression is critical for sensitivity to 5FU and RTX, was upregulated by vorinostat in wt- and downregulated in mut-p53 cells, suggesting an additional mechanism of the antiproliferative synergistic interactions observed. Overall these data add new insights in the mechanism of vorinostat antitumor effect and suggested that the association of vorinostat plus 5FU-FA and/or RTX should be clinically explored.

AB - Despite the introduction of several novel anticancer agents almost 50% of colorectal cancer (CRC) patients die for cancer suggesting the necessity of new therapeutical approaches. In this study we demonstrated that the HDAC inhibitor vorinostat exerted potent antiproliferative effect in a panel of mut- and wt-p53 human CRC cell lines. Moreover, in combination with 5-fluorouracil modulated by folinic acid (5FU-FA) or with Raltitrexed (RTX), both commonly used in the treatment of this disease, it showed a clear schedule-dependent synergistic antiproliferative interaction as demonstrated by calculating combination indexes. Only simultaneous, or 24 h pretreatment with vorinostat followed by either agent, produced synergistic effect paralleled by evident cell cycle perturbations with major S-phase arrest. Moreover, we provided for the first time evidences that vorinostat can overcome resistance to both 5FU and RTX. Downmodulation of Thymidilate synthase (TS) protein induced by vorinostat within 24 h, represented a key factor in enhancing the effects of both drugs in sensitive as well as resistant tumor cells. Furthermore, p53, whose wildtype expression is critical for sensitivity to 5FU and RTX, was upregulated by vorinostat in wt- and downregulated in mut-p53 cells, suggesting an additional mechanism of the antiproliferative synergistic interactions observed. Overall these data add new insights in the mechanism of vorinostat antitumor effect and suggested that the association of vorinostat plus 5FU-FA and/or RTX should be clinically explored.

KW - 5-fluorouracil

KW - Colorectal cancer

KW - HDAC inhibitor

KW - p53

KW - Raltitrexed

KW - Thimidilate synthase

KW - Vorinostat

UR - http://www.scopus.com/inward/record.url?scp=68149172699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68149172699&partnerID=8YFLogxK

M3 - Article

C2 - 19270508

AN - SCOPUS:68149172699

VL - 8

SP - 782

EP - 791

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 9

ER -